| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.18B | 31.69B | 28.89B | 26.26B | 24.75B | 23.05B |
| Gross Profit | 7.08B | 6.58B | 5.94B | 5.60B | 5.34B | 5.05B |
| EBITDA | 1.67B | 1.51B | 1.37B | 1.47B | 1.75B | 1.87B |
| Net Income | 916.00M | 776.00M | 677.00M | 824.00M | 966.00M | 1.05B |
Balance Sheet | ||||||
| Total Assets | 16.33B | 16.71B | 14.62B | 12.55B | 13.13B | 14.53B |
| Cash, Cash Equivalents and Short-Term Investments | 8.13B | 8.37B | 5.00B | 4.24B | 6.35B | 8.13B |
| Total Debt | 2.29B | 3.98B | 2.65B | 1.45B | 2.26B | 4.27B |
| Total Liabilities | 7.61B | 8.21B | 6.51B | 4.73B | 5.75B | 7.77B |
| Stockholders Equity | 8.72B | 8.51B | 8.12B | 7.82B | 7.38B | 6.76B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.18B | -825.00M | -1.46B | 453.00M | 151.00M |
| Operating Cash Flow | 0.00 | 1.84B | 771.00M | 304.00M | 1.28B | 1.08B |
| Investing Cash Flow | 0.00 | 598.00M | -827.00M | -1.21B | -690.00M | -274.00M |
| Financing Cash Flow | 0.00 | 933.00M | 815.00M | -1.20B | -2.36B | 3.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥17.70B | 15.33 | ― | 2.24% | -1.20% | -8.71% | |
77 Outperform | ¥18.18B | 17.64 | ― | 2.55% | 3.18% | -21.69% | |
75 Outperform | ¥9.36B | 13.27 | ― | 1.88% | 10.06% | 4.96% | |
74 Outperform | ¥14.05B | 15.42 | ― | 2.78% | 7.89% | -12.90% | |
68 Neutral | ¥9.03B | 9.08 | ― | 3.22% | 53.89% | ― | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
44 Neutral | ¥2.12B | ― | ― | ― | -18.74% | -1062.47% |
Study Overview: Poppins Corporation is conducting an observational follow-up study titled ‘Observational Follow-up Study Examining the Medium-term Effect on Non-inferiority of the Previous Training With the Digital Medical Device (DMD) Poppins Clinical for Cognitive and Musical Training in Addition to Bi-monthly Speech and Reading Therapy Sessions on the Reading and Writing Abilities of Pediatric Patients With Specific Learning Disorders Involving Reading and/or Writing Deficits (SLD Reading) Compared to a Control Group Receiving Weekly Speech and Reading Therapy Sessions (POPPINS-02-b, Ancillary Study to POPPINS-02).’ The study aims to evaluate the medium-term effects of the Poppins Clinical device on improving reading and writing abilities in children with specific learning disorders, compared to traditional therapy methods.